sur Bellevue Asset Management AG
Healthcare Investment Dynamics in 2025
High-value acquisitions and medical advancements are paving the way for a significant year in healthcare. With $250 billion in branded sales at risk, biopharma companies are aggressively securing new assets. Game-changing drugs, robotic surgery, and non-opioid treatments are entering the market, creating fresh investor momentum.
Mergers and acquisitions (M&A) are a key focus. The sector is ripe for M&A due to strong demand, ample capital, and a stabilizing interest rate environment. Johnson & Johnson's proposed $15 billion acquisition of Intra-Cellular affirmed this trend.
In biopharma, $1.3 trillion of capital supports acquisitions, backed by strong balance sheets and favorable interest rates. The Trump administration's regulatory climate further aids this surge.
In medtech, 2024 saw 48 M&A deals totaling $21 billion, and this momentum is set to continue. Innovations in obesity, pain management, and surgery, alongside FDA approvals, make 2025 promising for maturing innovations and investments in healthcare.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Bellevue Asset Management AG